While the recent adoption of a flexible clinical translation model in Hainan Province promises to accelerate biomedical innovation in China, it has also intensified concerns about patient safety, transparency, and misinformation. The success of this new approach is largely dependent on strengthening post-market oversight, access to clinical data, and strategic alignment with international bioethical guidelines.